SCHEMBL24123749

SCHEMBL24123749

CC(C)(C)c1ccc(N2CC(N3CCCC3)C2)cc1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 6/20 0.50
L3MBTL3 Q96JM7 5/20 0.50
HRH3 Q9Y5N1 2/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
MBTD1 Q05BQ5 3/20 0.42
ACACB O00763 2/20 0.40
HSD11B1 P28845 3/20 0.39
LMNA P02545 2/20 0.39
GAA P10253 1/20 0.39
CHRM2 P08172 1/20 0.39
CHRM1 P11229 1/20 0.39
TP53BP1 Q12888 2/20 0.38
L3MBTL4 Q8NA19 1/20 0.38
NPC1 O15118 1/20 0.38
MAPK1 P28482 1/20 0.38
MAPT P10636 1/20 0.38
KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25675635 0.97 L3MBTL1 (0.46) L3MBTL1L3MBTL3HRH3MEN1KMT2A
SCHEMBL10203058 0.85 L3MBTL3 (0.73) L3MBTL1L3MBTL3HRH3MEN1KMT2A
SCHEMBL19001066 0.84 HRH3 (0.52) L3MBTL1L3MBTL3HRH3MEN1KMT2A
SCHEMBL19001131 0.84 HRH3 (0.52) L3MBTL1L3MBTL3HRH3MEN1KMT2A
SCHEMBL23328247 0.84 HRH3 (0.52) L3MBTL1L3MBTL3HRH3MEN1KMT2A
SCHEMBL25675681 0.83 L3MBTL3 (0.71) L3MBTL1L3MBTL3HRH3MEN1KMT2A
SCHEMBL24123774 0.81 L3MBTL3 (0.68) L3MBTL1L3MBTL3HRH3MEN1KMT2A
SCHEMBL8352399 0.79 HSD11B1 (0.50) L3MBTL1MEN1KMT2AHSD11B1LMNA
SCHEMBL20234325 0.79 HSD11B1 (0.43) L3MBTL1L3MBTL3HRH3MEN1KMT2A
SCHEMBL23328251 0.78 KDM2B (0.53) L3MBTL1L3MBTL3HRH3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159540-A1 PYRAZOLO[3,4-d]PYRIMIDIN-3-ONE DERIVATIVE AS WEE-1 INHIBITOR PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE DERIVATIVE AS WEE-1 INHIBITOR (CN) 2023-05-25 US disclosed
US-20230159540-A1 PYRAZOLO[3,4-d]PYRIMIDIN-3-ONE DERIVATIVE AS WEE-1 INHIBITOR PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE DERIVATIVE AS WEE-1 INHIBITOR (CN) 2023-05-25 US disclosed
EP-4169919-A1 PYRAZOLO[3,4-D]PYRIMIDINE-3-KETONE DERIVATIVE AS WEE-1 INHIBITOR Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) 2023-04-26 EP disclosed
WO-2021254389-A1 PYRAZOLO[3,4-D]PYRIMIDINE-3-KETONE DERIVATIVE AS WEE-1 INHIBITOR 微境生物医药科技(上海)有限公司 2021-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159540-A1 PYRAZOLO[3,4-d]PYRIMIDIN-3-ONE DERIVATIVE AS WEE-1 INHIBITOR WEE1, WEE2, PEAK1 L3MBTL1 4572/4885L3MBTL3 4848/4885HRH3 3498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.